Abbott has secured the CE Mark for its next-generation Amulet 360™ device, strengthening its position in the rapidly evolving left atrial appendage (LAA) closure market.
The device is designed for people with atrial fibrillation (AFib) who are at risk of stroke, particularly those who may not be suitable for long-term blood-thinning therapy.
Why This Matters
• Market-share opportunity: Abbott CEO Robert Ford estimates the LAA closure market at approximately $2 billion, with the leading competitor holding around 90% share.
• Direct competition with Watchman: Abbott’s Amulet competes directly with Boston Scientific’s Watchman, the current market leader.
• Product differentiation: Amulet 360 is engineered to improve how the implant conforms to and seals the LAA, potentially supporting a more seamless implantation experience for physicians.
• Clinical validation: The device met safety and effectiveness benchmarks in the VERITAS study, supporting the CE Mark decision.
• Expansion across Europe: Abbott plans to introduce Amulet 360 across European markets in the coming weeks.
Competitive Landscape
The LAA closure market is becoming increasingly competitive as MedTech companies target the growing AFib population.
Key players include:
- Abbott – Amulet / Amulet 360
- Boston Scientific – Watchman
- Medtronic – Penditure LAA Exclusion System
- AtriCure – AtriClip
- Edwards Lifesciences – LAA clip technology
Abbott has also completed its FDA submission for Amulet 360, potentially opening another major growth opportunity in the U.S.
Strategic Takeaway
Amulet 360 is more than a product refresh; it represents Abbott’s strategic attempt to capture share in a concentrated, high-value market.
With improving clinical evidence, product innovation and growing competition, LAA closure could become an increasingly important battleground in structural heart and electrophysiology.
#Abbott #BostonScientific #Medtronic #AtriCure #EdwardsLifesciences #MedTech #Cardiology #StructuralHeart #AtrialFibrillation #AFib #LAAClosure #MedicalDevices #Healthcare #MarketIntelligence #MedTechInnovation